![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Results of Auspex Pharmaceuticals' Phase 3 Registration Trial of SD-809 to be Presented at AAN Annual Meeting
March 27, 2015 07:00 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Reports Fourth Quarter 2014 Results and Business Highlights
March 16, 2015 16:01 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex to Present at the Cowen Healthcare Conference
February 23, 2015 06:30 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
February 03, 2015 06:30 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex to Present at the 2015 Leerink Global Healthcare Conference
February 02, 2015 16:00 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 28, 2015 16:00 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Announces Pricing of Follow on Offering
January 23, 2015 07:27 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Announces Proposed Public Offering of Common Stock
January 21, 2015 16:32 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
January 14, 2015 13:34 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 14, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Announces SD-1077 Program for the Potential Treatment of Parkinson's Disease and Related Movement Disorders
January 12, 2015 09:19 ET
|
Auspex Pharmaceuticals, Inc.
Auspex to Acquire Remaining Worldwide Rights to SD-1077 Through Purchase of Imphar AG
Clinical Proof-Of-Concept Data for SD-1077 Versus Levodopa Expected in 2016
LA JOLLA, Calif., Jan. 12, 2015...